Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

Tumor protein p53 (TP53) is the most frequently mutated gene in cancer1,2. In patients with myelodysplastic syndromes (MDS), TP53 mutations are associated with high-risk disease3,4, rapid transformation to acute myeloid leukemia (AML)5, resistance to conventional therapies6,7,8 and dismal outcomes9....

Podrobná bibliografie
Hlavní autoři:	Bernard, E, Nannya, Y, Hasserjian, RP, Boultwood, J, Pellagatti, A
Médium:	Journal article
Jazyk:	English
Vydáno:	Springer Nature 2020

Podobné jednotky

NRAS, FLT3 and TP53 mutations in patients with myelodysplastic syndrome and a del(5q).
Autor: Fidler, C, a další
Vydáno: (2004)

TP53 Alterations in Myelodysplastic Syndromes and Acute Myeloid Leukemia
Autor: Ramy Rahmé, a další
Vydáno: (2023-04-01)

Rare case of myelodysplastic syndrome with near-tetraploidy and TP53 mutation
Autor: Čolović Nataša, a další
Vydáno: (2023-01-01)

Clinical outcomes and characteristics of patients with TP53-mutated myelodysplastic syndromes
Autor: Lijuan Zhang, a další
Vydáno: (2023-12-01)

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups
Autor: Haase, D, a další
Vydáno: (2019)

SF3B1 mutant myelodysplastic syndrome: Recent advances
Autor: Pellagatti, A, a další
Vydáno: (2020)

TP53 mutation in newly diagnosed acute myeloid leukemia and myelodysplastic syndrome
Autor: Pimjai Niparuck, a další
Vydáno: (2021-10-01)

Gene expression profiling in the myelodysplastic syndromes.
Autor: Pellagatti, A, a další
Vydáno: (2005)

Splicing factor gene mutations in the myelodysplastic syndromes: impact on disease phenotype and therapeutic applications.
Autor: Pellagatti, A, a další
Vydáno: (2016)

Molecular characterization of AML‐MRC reveals TP53 mutation as an adverse prognostic factor irrespective of MRC‐defining criteria, TP53 allelic state, or TP53 variant allele frequency
Autor: Davidson Zhao, a další
Vydáno: (2023-03-01)

The role of splicing factor mutations in the pathogenesis of the myelodysplastic syndromes.
Autor: Boultwood, J, a další
Vydáno: (2014)

TP53-mutated myelodysplastic syndrome and acute myeloid leukemia: biology, current therapy, and future directions
Autor: Daver, NG, a další
Vydáno: (2022)

Single-molecule DNA sequencing of acute myeloid leukemia and myelodysplastic syndromes with multiple TP53 alterations
Autor: Laurence Lodé, a další
Vydáno: (2018-01-01)

Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis
Autor: Rashmi Kanagal-Shamanna, a další
Vydáno: (2021-03-01)

A tale of two alleles: TP53 and transformation in MPNs
Autor: Brierley, C, a další
Vydáno: (2022)

High and low, but not intermediate, PRAME expression levels are poor prognostic markers in myelodysplastic syndrome at disease presentation
Autor: Liberante, F, a další
Vydáno: (2013)

High and low, but not intermediate, PRAME expression levels are poor prognostic markers in myelodysplastic syndrome at disease presentation.
Autor: Liberante, F, a další
Vydáno: (2013)

Transplantation for therapy-related, TP53-mutated myelodysplastic syndrome – not because we can, but because we should
Autor: Corey Cutler
Vydáno: (2017-12-01)

Presence of new mutations in the TP53 gene in patients with low-risk myelodysplastic syndrome: two case reports
Autor: Fernando Barroso Duarte, a další
Vydáno: (2017-05-01)

Splicing factor mutations in the myelodysplastic syndromes: target genes and therapeutic approaches
Autor: Armstrong, R, a další
Vydáno: (2017)

Bladder Myeloid Sarcoma with TP53 mutated Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap syndrome: Response to Decitabine-Venetoclax regimen
Autor: Nikeeta Mandhan, a další
Vydáno: (2022-01-01)

Clonality in the myelodysplastic syndromes.
Autor: Boultwood, J, a další
Vydáno: (2001)

To target the untargetable: elucidation of synergy of APR-246 and azacitidine in TP53 mutant myelodysplastic syndromes and acute myeloid leukemia
Autor: David A. Sallman
Vydáno: (2020-06-01)

PB1913: SYNERGISTIC EFFECTS OF DECITABINE AND APR-246 IN TP53 P.248Q-MUTATED MYELODYSPLASTIC SYNDROME
Autor: Y. Fang, a další
Vydáno: (2022-06-01)

Prognostic heterogeneity and clonal dynamics within distinct subgroups of myelodysplastic syndrome and acute myeloid leukemia with TP53 disruptions
Autor: Shyam A. Patel, a další
Vydáno: (2023-11-01)

Pulmonary infection associated with immune dysfunction is associated with poor prognosis in patients with myelodysplastic syndrome accompanied by TP53 abnormalities
Autor: Yi Chen, a další
Vydáno: (2023-11-01)

Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia
Autor: Kathy L. McGraw, a další
Vydáno: (2016-08-01)

Molecular pathogenesis of the myelodysplastic syndromes
Autor: Boultwood, J, a další
Vydáno: (1999)

Haploinsufficiency of ribosomal proteins and p53 activation in anemia: Diamond-Blackfan anemia and the 5q- syndrome.
Autor: Boultwood, J, a další
Vydáno: (2012)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
Autor: Melania Tesio
Vydáno: (2023-02-01)

Telomere length in myelodysplastic syndromes.
Autor: Boultwood, J, a další
Vydáno: (1995)

Synergistic effects of PRIMA-1Met (APR-246) and 5-azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia
Autor: Nabih Maslah, a další
Vydáno: (2020-06-01)

Allogeneic haematopoietic stem cell transplantation with decitabine-containing preconditioning regimen in TP53-mutant myelodysplastic syndromes: A case study
Autor: Yuxin Wang, a další
Vydáno: (2022-07-01)

Gene expression profiling in 5q-syndrome and myelodysplastic syndromes.
Autor: Pellagatti, A, a další
Vydáno: (2003)

TP53 and TP53-associated genes are correlated with the prognosis of paediatric neuroblastoma
Autor: Haiwei Wang, a další
Vydáno: (2022-06-01)

The role and impact of Del(5q) and TP53 mutations on haematopoietic stem and progenitor cells during the progression of Myelodysplastic Syndrome to Acute Myeloid Leukaemia
Autor: Doolittle, H
Vydáno: (2017)

Genomic Characterization of TP53–Wild-Type Esophageal Carcinoma
Autor: Alexander Quaas, a další
Vydáno: (2019-01-01)

Gene Expression Profiling of CD34(+) Cells in Patients with Myelodysplastic Syndromes
Autor: Pellagatti, A, a další
Vydáno: (2008)

P066: Variant overlooked: A partial deficiency TP53 allele that skirts interpretation criteria
Autor: Lisa Lansdon, a další
Vydáno: (2023-01-01)

Clinical and biological implications of driver mutations in myelodysplastic syndromes.
Autor: Papaemmanuil, E, a další
Vydáno: (2013)